Review ArticleReview

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors

Jennifer Kleponis, Richard Skelton and Lei Zheng
Cancer Biology & Medicine September 2015, 12 (3) 201-208; DOI: https://doi.org/10.7497/j.issn.2095-3941.2015.0046

References

  1. 1.↵
    2. Kantoff PW,
    3. Higano CS,
    4. Shore ND,
    5. Berger ER,
    6. Small EJ,
    7. Penson DF, et al.
    Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411–422.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Hodi FS,
    3. O'Day SJ,
    4. McDermott DF,
    5. Weber RW,
    6. Sosman JA,
    7. Haanen JB, et al.
    Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Hamid O,
    3. Robert C,
    4. Daud A,
    5. Hodi FS,
    6. Hwu WJ,
    7. Kefford R, et al.
    Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134–144.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    2. Robert C,
    3. Long GV,
    4. Brady B,
    5. Dutriaux C,
    6. Maio M,
    7. Mortier L, et al.
    Nivolumab in previously untreated melanoma without B^AF mutation. N Engl J Med 2015;372:320–330.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    2. Brahmer J,
    3. Reckamp KL,
    4. Baas P,
    5. Crino L,
    6. Eberhardt WE,
    7. Poddubskaya E, et al.
    Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123–135.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Topalian SL,
    3. Drake CG,
    4. Pardoll DM.
    Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450–461.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Chambers CA,
    3. Kuhns MS,
    4. Egen JG,
    5. Allison JP.
    CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565–594.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Egen JG,
    3. Kuhns MS,
    4. Allison JP.
    CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611–618.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    2. van der Merwe PA,
    3. Bodian DL,
    4. Daenke S,
    5. Linsley P,
    6. Davis SJ.
    CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997;185:393–403.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Camacho LH.
    CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med 2015;4:661–672.
    OpenUrl
  11. 11.↵
    2. Barbee MS,
    3. Ogunniyi A,
    4. Horvat TZ,
    5. Dang TO.
    Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology. Ann Pharmacother 2015;49:907–937.
    OpenUrlCrossRefPubMed
  12. 12.↵
    2. Lynch TJ,
    3. Bondarenko I,
    4. Luft A,
    5. Serwatowski P,
    6. Barlesi F,
    7. Chacko R, et al.
    Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046–2054.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    2. Yang JC,
    3. Hughes M,
    4. Kammula U,
    5. Royal R,
    6. Sherry RM,
    7. Topalian SL, et al.
    Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825–830.
    OpenUrlCrossRefWeb of Science
  14. 14.↵
    2. Royal RE,
    3. Levy C,
    4. Turner K,
    5. Mathur A,
    6. Hughes M,
    7. Kammula US, et al.
    Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010;33:828–833.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    2. Keir ME,
    3. Butte MJ,
    4. Freeman GJ,
    5. Sharpe AH.
    PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677–704.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    2. Spranger S,
    3. Spaapen RM,
    4. Zha Y,
    5. Williams J,
    6. Meng Y,
    7. Ha TT, et al.
    Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5:200ra116.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    2. Flies DB,
    3. Chen L.
    The new B7s: playing a pivotal role in tumor immunity. J Immunother 2007;30:251–260.
    OpenUrlCrossRefWeb of Science
  18. 18.↵
    2. Topalian SL,
    3. Hodi FS,
    4. Brahmer JR,
    5. Gettinger SN,
    6. Smith DC,
    7. McDermott DF, et al.
    Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–2454.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    2. Topalian SL,
    3. Sznol M,
    4. McDermott DF,
    5. Kluger HM,
    6. Carvajal RD,
    7. Sharfman WH, et al.
    Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020–1030.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    2. Robert C,
    3. Schachter J,
    4. Long GV,
    5. Arance A,
    6. Grob JJ,
    7. Mortier L, et al.
    Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015;372:2521–2532.
    OpenUrlCrossRefPubMed
  21. 21.↵
    2. Waqar SN,
    3. Morgensztern D.
    Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era? Expert Rev Clin Immunol 2015;11:871–873.
    OpenUrl
  22. 22.↵
    2. Le DT,
    3. Uram JN,
    4. Wang H,
    5. Bartlett BR,
    6. Kemberling H,
    7. Eyring AD, et al.
    PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015;372:2509–2520.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Gunturi A,
    3. McDermott DF.
    Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol 2014;15:137–146.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Powles T,
    3. Eder JP,
    4. Fine GD,
    5. Braiteh FS,
    6. Loriot Y,
    7. Cruz C, et al.
    MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558–562.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    2. Pardoll DM.
    The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–264.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    2. Blackburn SD,
    3. Shin H,
    4. Haining WN,
    5. Zou T,
    6. Workman CJ,
    7. Polley A, et al.
    Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009;10:29–37.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    2. Grosso JF,
    3. Goldberg MV,
    4. Getnet D,
    5. Bruno TC,
    6. Yen HR,
    7. Pyle KJ, et al.
    Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009;182:6659–6669.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    2. Baitsch L,
    3. Legat A,
    4. Barba L,
    5. Fuertes Marraco SA,
    6. Rivals JP,
    7. Baumgaertner P, et al.
    Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 2012;7:e30852.
  29. 29.
    2. Fourcade J,
    3. Sun Z,
    4. Benallaoua M,
    5. Guillaume P,
    6. Luescher IF,
    7. Sander C, et al.
    Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010;207:2175–2186.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    2. Sakuishi K,
    3. Apetoh L,
    4. Sullivan JM,
    5. Blazar BR,
    6. Kuchroo VK,
    7. Anderson AC.
    Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010;207:2187–2194.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    2. Curran MA,
    3. Montalvo W,
    4. Yagita H,
    5. Allison JP.
    PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275–4280.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    2. Duraiswamy J,
    3. Kaluza KM,
    4. Freeman GJ,
    5. Coukos G.
    Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73:3591–3603.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    2. Spranger S,
    3. Koblish HK,
    4. Horton B,
    5. Scherle PA,
    6. Newton R,
    7. Gajewski TF.
    Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014;2:3.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    2. Soliman HH,
    3. Jackson E,
    4. Neuger T,
    5. Dees EC,
    6. Harvey RD,
    7. Han H, et al.
    A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 2014;5:8136–8146.
    OpenUrlCrossRefPubMed
  35. 35.↵
    2. Wolchok JD,
    3. Kluger H,
    4. Callahan MK,
    5. Postow MA,
    6. Rizvi NA,
    7. Lesokhin AM, et al.
    Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122–133.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    2. Larkin J,
    3. Chiarion-Sileni V,
    4. Gonzalez R,
    5. Grob JJ,
    6. Cowey CL,
    7. Lao CD, et al.
    Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015;373:23–34.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Lipson EJ,
    3. Sharfman WH,
    4. Drake CG,
    5. Wollner I,
    6. Taube JM,
    7. Anders ^A, et al.
    Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013;19:462–468.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    2. Taube JM,
    3. Klein A,
    4. Brahmer JR,
    5. Xu H,
    6. Pan X,
    7. Kim JH, et al.
    Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064–5074.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    2. Brahmer JR,
    3. Tykodi SS,
    4. Chow LQ,
    5. Hwu WJ,
    6. Topalian SL,
    7. Hwu P, et al.
    Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–2465.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    2. Beatty GL,
    3. Chiorean EG,
    4. Fishman MP,
    5. Saboury B,
    6. Teitelbaum UR,
    7. Sun W, et al.
    CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans. Science 2011;331:1612–1616.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    2. Clark CE,
    3. Hingorani SR,
    4. Mick R,
    5. Combs C,
    6. Tuveson DA,
    7. Vonderheide RH.
    Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67:9518–9527.
    OpenUrlAbstract/FREE Full Text
  42. 42.
    2. Llosa NJ,
    3. Cruise M,
    4. Tam A,
    5. Wicks EC,
    6. Hechenbleikner EM,
    7. Taube JM, et al.
    The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43–51.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    2. Lutz ER,
    3. Wu AA,
    4. Bigelow E,
    5. Sharma R,
    6. Mo G,
    7. Soares K, et al.
    Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014;2:616–631.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    2. Soares KC,
    3. Rucki AA,
    4. Wu AA,
    5. Olino K,
    6. Xiao Q,
    7. Chai Y, et al.
    PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother 2015;38:1–11.
    OpenUrlCrossRefPubMed
  45. 45.↵
    2. Zheng L,
    3. Xue J,
    4. Jaffee E,
    5. Habtezion A.
    Role of Immune Cells and Immune-Based Therapies in Pancreatitis and Pancreatic Ductal Adenocarcinoma. Gastroenterology 2013;144:1230–1240.
    OpenUrlCrossRefPubMed
  46. 46.↵
    2. Lutz ER,
    3. Kinkead H,
    4. Jaffee EM,
    5. Zheng L.
    Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. Oncoimmunology 2014;3:e962401.
  47. 47.↵
    2. Le DT,
    3. Lutz E,
    4. Uram JN,
    5. Sugar EA,
    6. Onners B,
    7. Solt S, et al.
    Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013;36:382–389.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    2. Salman B,
    3. Zhou D,
    4. Jaffee EM,
    5. Edil BH,
    6. Zheng L.
    Vaccine therapy for pancreatic cancer. Oncoimmunology 2013;2:e26662.
  49. 49.↵
    2. Jaffee EM,
    3. Hruban RH,
    4. Biedrzycki B,
    5. Laheru D,
    6. Schepers K,
    7. Sauter PR, et al.
    Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145–156.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    2. Laheru D,
    3. Lutz E,
    4. Burke J,
    5. Biedrzycki B,
    6. Solt S,
    7. Onners B, et al.
    Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008;14:1455–1463.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    2. Lutz E,
    3. Yeo CJ,
    4. Lillemoe KD,
    5. Biedrzycki B,
    6. Kobrin B,
    7. Herman J, et al.
    A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011;253:328–335.
    OpenUrlCrossRefPubMed
  52. 52.↵
    2. Thomas AM,
    3. Santarsiero LM,
    4. Lutz ER,
    5. Armstrong TD,
    6. Chen YC,
    7. Huang LQ, et al.
    Mesothelin- spe cific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297–306.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    2. Zheng L.
    Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies? Immunotherapy 2014;6:1017–1020.
    OpenUrl
  54. 54.↵
    2. Karyampudi L,
    3. Lamichhane P,
    4. Scheid AD,
    5. Kalli KR,
    6. Shreeder B,
    7. Krempski JW, et al.
    Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res 2014;74:2974–2985.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    2. Li B,
    3. VanRoey M,
    4. Wang C,
    5. Chen TH,
    6. Korman A,
    7. Jooss K.
    Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 2009;15:1623–1634.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    2. Fu J,
    3. Kanne DB,
    4. Leong M,
    5. Glickman LH,
    6. McWhirter SM,
    7. Lemmens E, et al.
    STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med 2015;7:283ra52.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords